

Author Index for Volume 17

- AASK Pilot Study Investigators, xii,
 17(4S):1S, 17(4S):3S,
 17(4S):17S,
 17(4S):34S,
 17(4S):40S,
 17(4S):47S
 Agodoa LY 17(4S):1S,
 17(4S):3S
 Ahern DK, 46
 Akiyama T, 294
 Anderson G, 509
 Anderson JL, 17(3S):17S
 Anderson MM, Jr, 407
 Antman EM, 357
 Ash A, 177

 Backhouse M, 304
 Bailey G, 23, 271
 Ballantyne CM, 550
 Bandai Y, 476
 Bartholow B, 209
 Beck RW, 407
 Begg CB, 176
 Bell L, 304
 Berkey CS, 357
 Berlin JA, 191
 Bigger JT, Jr, 46
 Boissel J-P, 130
 Bossard N, 130
 Bradham KH, 33
 Branyon M, 46
 Brookmeyer R, 75
 Brown BW, 266
 Brown L, 536
 Buchbinder S, 209
 Budeiri D, 60
 Burek K, 226
 Buxton AE, 17(3S):47S
 Buxton M, 304
 Byington RP, 33

 Camm AJ, 17(3S):4S
 Campion J, 46
 Campos-Perez Y, 258
 Cantor AB, 111
 Carmody S, 23, 271
 Carranza-Madrigal J, 258
 Carroll D, 1

 Catalano PM, 442
 Chamberlain RM, 494
 Charleston J, 17(4S):17S,
 17(4S):47S
 Chavez-Carbajal F, 258
 Clemens JD, 442
 Cole T, 536
 Cornell CE, 17(4S):40S
 Cottingham V, 23, 271
 Crow S, 415
 Crowley J, 353
 Curet LB, 442

 Davidson C, 117
 Davidson GK, 117
 Davis BR, 536
 DeBrughe J, 17(4S):17S
 DeMets D, 509
 DerSimonian R, 442
 Diehl Boly L, 407
 Digitalis Investigation
 Group, 77
 Dolecek TA, 33
 Dorman JC, 60
 Douglas JM, Jr, 209
 Douglas M, 17(4S):17S,
 17(4S):34S
 Duggan J, 46

 Edwards JS, 117
 Egan D, 23, 271
 Eisenberg JM, 304
 Elizur-Leiberman E, 201
 Ellenberg SS, 354
 Engin K, 316
 Espeland MA, 33
 Estacio RO, 242
 Esterlitz JR, 442
 Ewell MG, 442

 Faille C, 415
 Faulkner M, 17(4S):17S,
 17(4S):40S,
 17(4S):47S
 Fisher LD, 423
 Fogoros RN, 17(3S):37S
 Follick MJ, 46
 Fowler G, 235
 Freedman L, 509

 Friedman SA, 442

 Gavaghan DJ, 1
 Gibson D, 71
 Glasscock R, 17(4S):1S,
 17(4S):3S
 Glick H, 304
 Goldenberg RL, 442
 Gorkin L, 46
 Gotto AM, Jr, 550
 Gøtzsche PC, 285
 Gray S, 235
 Greene PG, 17(4S):17S,
 17(4S):34,
 17(4S):40
 Greenhouse SW, 474
 Grim C, 17(4S):34S

 Haakenson C, 294
 Hallstrom A, 294
 Handshaw K, 46
 Hankin B, 415
 Harvey A, 71
 Hauschke D, 347
 Hauth JC, 442
 Hawkins CM, 536
 Hayashi K, 99
 Hennessy M, 209
 Herd JA, 550
 Herrera-Abaraca JE, 258
 Hershey N, 183
 Hertert S, 23, 271
 Hoen H, 33
 Holme I, 13
 Hjorth M, 372
 Hoaglin DC, 435
 Holmberg E, 372
 Hudmon KS, 494

 Jacobson S-L, 442
 Jadad AR, 1
 Jenkinson C, 1
 Joffe GM, 442
 Johnson Nagel N, 242
 Johnson P, 23, 271
 Jones CA, 17(4S):17S
 Judson F, 209

 Kadane JB, 352

Author Index for Volume 17

- AASK Pilot Study Investigators, xii,
 17(4S):1S, 17(4S):3S,
 17(4S):17S,
 17(4S):34S,
 17(4S):40S,
 17(4S):47S
 Agodoa LY 17(4S):1S,
 17(4S):3S
 Ahern DK, 46
 Akiyama T, 294
 Anderson G, 509
 Anderson JL, 17(3S):17S
 Anderson MM, Jr, 407
 Antman EM, 357
 Ash A, 177

 Backhouse M, 304
 Bailey G, 23, 271
 Ballantyne CM, 550
 Bandai Y, 476
 Bartholow B, 209
 Beck RW, 407
 Begg CB, 176
 Bell L, 304
 Berkey CS, 357
 Berlin JA, 191
 Bigger JT, Jr, 46
 Boissel J-P, 130
 Bossard N, 130
 Bradham KH, 33
 Branyon M, 46
 Brookmeyer R, 75
 Brown BW, 266
 Brown L, 536
 Buchbinder S, 209
 Budeiri D, 60
 Burek K, 226
 Buxton AE, 17(3S):47S
 Buxton M, 304
 Byington RP, 33

 Camm AJ, 17(3S):4S
 Campion J, 46
 Campos-Perez Y, 258
 Cantor AB, 111
 Carmody S, 23, 271
 Carranza-Madrigal J, 258
 Carroll D, 1

 Catalano PM, 442
 Chamberlain RM, 494
 Charleston J, 17(4S):17S,
 17(4S):47S
 Chavez-Carbajal F, 258
 Clemens JD, 442
 Cole T, 536
 Cornell CE, 17(4S):40S
 Cottingham V, 23, 271
 Crow S, 415
 Crowley J, 353
 Curet LB, 442

 Davidson C, 117
 Davidson GK, 117
 Davis BR, 536
 DeBruege J, 17(4S):17S
 DeMets D, 509
 DerSimonian R, 442
 Diehl Boly L, 407
 Digitalis Investigation
 Group, 77
 Dolecek TA, 33
 Dorman JC, 60
 Douglas JM, Jr, 209
 Douglas M, 17(4S):17S,
 17(4S):34S
 Duggan J, 46

 Edwards JS, 117
 Egan D, 23, 271
 Eisenberg JM, 304
 Elizur-Leiberman E, 201
 Ellenberg SS, 354
 Engin K, 316
 Espeland MA, 33
 Estacio RO, 242
 Esterlitz JR, 442
 Ewell MG, 442

 Faille C, 415
 Faulkner M, 17(4S):17S,
 17(4S):40S,
 17(4S):47S
 Fisher LD, 423
 Fogoros RN, 17(3S):37S
 Follick MJ, 46
 Fowler G, 235
 Freedman L, 509

 Friedman SA, 442

 Gavaghan DJ, 1
 Gibson D, 71
 Glasscock R, 17(4S):1S,
 17(4S):3S
 Glick H, 304
 Goldenberg RL, 442
 Gorkin L, 46
 Gotto AM, Jr, 550
 Gøtzsche PC, 285
 Gray S, 235
 Greene PG, 17(4S):17S,
 17(4S):34,
 17(4S):40
 Greenhouse SW, 474
 Grim C, 17(4S):34S

 Haakenson C, 294
 Hallstrom A, 294
 Handshaw K, 46
 Hankin B, 415
 Harvey A, 71
 Hauschke D, 347
 Hauth JC, 442
 Hawkins CM, 536
 Hayashi K, 99
 Hennessy M, 209
 Herd JA, 550
 Herrera-Abaraca JE, 258
 Hershey N, 183
 Hertert S, 23, 271
 Hoen H, 33
 Holme I, 13
 Hjorth M, 372
 Hoaglin DC, 435
 Holmberg E, 372
 Hudmon KS, 494

 Jacobson S-L, 442
 Jadad AR, 1
 Jenkinson C, 1
 Joffe GM, 442
 Johnson Nagel N, 242
 Johnson P, 23, 271
 Jones CA, 17(4S):17S
 Judson F, 209

 Kadane JB, 352

- Kakizoe T, 476
 Kappelle LJ, 33
 Kiefer S, 17(4S):17S
 Kinney MR, 46
 Kipnis V, 509
 Kirk KA, 17(4S):1S,
 17(4S):3S,
 17(4S):17S,
 17(4S):34S
 Kiuchi T, 476
 Klebanoff MA, 442
 Knatterud GL, 290, 437,
 473
 Konishi M, 476
 Kopple JD 17(4S) 40S, 40
 Korn EL, 526
 Kosuge T, 476
 Kusek JW, 17(4S):1S,
 17(4S):3S,
 17(4S):17S,
 17(4S):34S,
 17(4S):40S,
 17(4S):47S

 Lamborn KR, 547
 Lancaster S, 46
 Lancaster T, 235
 Laska E, 387
 Lau J, 357
 Law MG, 221
 LCAS Investigators, 551
 Leavitt FJ, 201
 Lee JY, 17(4S):1S,
 17(4S):3S,
 17(4S):17S,
 17(4S):34S,
 17(4S):40S,
 17(4S):47S
 Levell B, 17(4S):17S,
 17(4S):46S
 Levine RJ, 442
 Li N, 268
 Li Wan Po A, 60
 Lorimor RJ, 494
 Luca S, 123

 MacQueen K, 209
 Margitic SE, 33
 McKirman DJ, 209
 McQuay HJ, 1
 Meinert CL, 273
 Meisner M, 387
 Milligan S, 17(4S):34S,
 17(4S):40S,
 17(4S):47S
 Moore RA, 1
 Morris CD, 442
 Mosteller F, 356
 Moyé LA, 537

 Naydeck BL, 226
 Ness RB, 191
 Ng T-H, 349
 Norris K, 17(4S):17S,
 17(4S):47S

 Ohashi Y, 476
 O'Rourke K, 69, 350

 Parmar M, 71
 Pater J, 548
 Petrulis AS, 442
 Pilpel D, 201
 Pocock SJ, 292
 Powers SN, 17(4S):17S
 Pownall HJ, 550
 Prentice R, 509
 Probstfield J, 23, 271
 Prystowsky EN,
 17(3S):1S,
 17(3S):28S

 Randall OS, 17(4S):3S
 Raymond EG, 442
 Retta TM, 17(4S):17S
 Reynolds DJM, 1
 Rigau-Perez JG, 442
 Rödger S, 372
 Rossouw J, 509

 Sacks F, 536
 Salazar LA, 258
 Sather MR, 294

 Savage S, 242
 Schemper M, 343
 Schrier RW, 242
 Schron EB, 46
 Schulman KA, 304
 Sculpher M, 304
 Shea S, 46
 Sheon A, 209
 Sibai BM, 442
 Siegel C, 387
 Silagy C, 235
 Simon R, 526
 Simpson S, 550
 Smith DE, 17(4S):17S,
 17(4S):34S,
 17(4S):40S
 Smith TL, 343
 Sopko GS, 226
 Steinbach G, 494
 Steinijans VW, 347
 Stoltzfus C, 494
 Stylianou M, 46
 Suchanek Hudmon K, 495
 Sun H, 268
 Sutton-Tyrrell K, 226, 415
 Sylvia SC, 46

 Taube A, 372
 Terranova R, 123
 Toto RD, 17(4S):3S
 Trudel J, 415

 Walker AM, 99
 Wang CY, 509
 Ward H, 17(4S):17S
 West MS, 550
 Westin J, 372
 Whelton PK, 17(4S):17S,
 17(4S) 34S
 Williams GW, 72
 Winn RJ, 494
 Wittes J, 509
 Wright JT, 17(4S):1S
 Wright JT, Jr, 17(4S):3S

Subject Index for Volume 17

AASK PILOT STUDY

Appointment Attendance, Pill Counts, and Achievement of Goal Blood Pressure in the African American Study of Kidney Disease and Hypertension Pilot Study, 17(4S):34S

Design and Baseline Characteristics of Participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):3S

Effect of Blood Pressure Control and Antihypertensive Drug Regimen on Quality of Life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):40S

Overview, 17(4S):1S

Participant Satisfaction in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):47S

Recruitment Experience in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):17S

ACTIVE CONTROL EQUIVALENCE STUDIES

A Note On Conventional Null Hypothesis Testing in Active Control Equivalence Studies (letter), 347, (letter reply), 349

ADVERSE DRUG EXPERIENCES

Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

AMIODARONE

Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrhythmias, 17(3S):37S

ANGIOGRAPHY

The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, Methods, and Baseline Data of a Trial of Fluvastatin in Patients without Severe Hypercholesterolemia, 550

ANTIARRHYTHMIC AGENTS

Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S

ANTIVIRAL DRUG

Preliminary Results of Beta-Interferon Treatment in the Elderly, 123

ATHEROSCLEROSIS

The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, Methods, and Baseline Data of a Trial of Fluvastatin in Patients without Severe Hypercholesterolemia, 550
Registry of Multicenter Clinical Trials: 14th and 15th Report 1992-1993. On Behalf of the Council on Thrombosis and Haemostasis of the International Society and Federation of Cardiology, and the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 130

AUDITS

Do Low Observed Error Rates Lessen the Need for Study-Specific Data Quality Audits (letter)?, 69
Response to O'Rourke (letter), 71

AUTONOMY OF DOCTORS AND PATIENTS

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201

BASAL NOCTURNAL SECRETION

Differences in Basal Nocturnal, Meal-Stimulated, and Pentagastrin-Stimulated Gastric Secretion Values in a Sample of Healthy Volunteers in Basal Conditions and Under Ranitidine Influence, 258

BAYESIAN ANALYSIS

Comments on Bayesian and Frequentist Analysis and Interpretation of Clinical Trials, 423

BETA BLOCKERS

Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S

BINARY DATA

Sample Size Calculations for Within-Patient Comparisons with a Binary or Survival Endpoint, 221

BIOLOGY

Biological Rationale and Clinical Experience with Hyperthermia, 316

BIOMETRY

Case Studies in Biometry (book review), 266

BLINDING ANALYSES

Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?, 1

Blinding During Data Analysis and Writing of Manuscripts, 285

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294

BYPASS ANGIOPLASTY**REVASCULARIZATION INVESTIGATION (BARI)**

Organizational Structure and Communication Strategies of the Bypass Angioplasty Revascularization Investigation: A Multicenter Clinical Trial, 226

CALCIUM

Trial of Calcium for Preeclampsia Prevention (CPEP): Rationale, Design, and Methods (design paper), 442

CANCER PREVENTION

Participants' Perceptions of a Phase I Colon Cancer Chemoprevention Trial, 495

CANCER TREATMENT

Biological Rationale and Clinical Experience with Hyperthermia, 316

CARDIAC ARRHYTHMIA

Clinical Trial Enrollers vs. Nonenrollers: The Cardiac Arrhythmia Suppression Trial (Cast) Recruitment and Enrollment Assessment in Clinical Trials (REACT) Project, 46

Clinical Trials of Arrhythmia Management: Methods or Madness, 17(3S):4S

Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM): A Critical Appraisal, 17(3S):28S

Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrhythmias, 17(3S):37S

Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(3S):47S

CASE STUDIES

Case Studies in Biometry (book review), 266

CAST

Clinical Trial Enrollers vs. Nonenrollers: The Cardiac Arrhythmia Suppression Trial (Cast) Recruitment and Enrollment Assessment in Clinical Trials (REACT) Project, 46

CHEMOPREVENTION

Participants' Perceptions of a Phase I Colon Cancer Chemoprevention Trial, 494

CHOLESTEROL

The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, Methods, and Baseline Data of a Trial of Fluvastatin in Patients without Severe Hypercholesterolemia, 550

Maximizing Recruitment Efforts in a Drug Lipid-Lowering Trial with

- Dietary Intervention to Lower LDL Cholesterol, 33
- Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13
- CHRONIC VIRAL LIVER DISEASE**
- Preliminary Results of Beta-Interferon Treatment in the Elderly, 123
- CLINICAL DECISION MAKING**
- The Economic Evaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304
- CLINICAL EFFECTIVENESS**
- The Economic Evaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304
- CLINICAL INVESTIGATOR**
- The Clinical Investigator as Target, 183
- CLINICAL MEASUREMENT**
- Clinical Measurement in Drug Evaluation* (book review), 354
- CLINICAL TRIAL REGISTRY**
- Registry of Multicenter Clinical Trials: 14th and 15th Report 1992-1993. On Behalf of the Council on Thrombosis and Haemostasis of the International Society and Federation of Cardiology, and the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 130
- CLINICAL TRIALS**
- Analyzing Survival Data from Clinical Trials and Observational Studies* (book review), 353
- Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509
- Clinical Trial Enrollers vs. Nonenrollers: The Cardiac Arrhythmia Suppression Trial (Cast)
- Recruitment and Enrollment Assessment in Clinical Trials (REACT) Project, 46
- Clinical Trials of Arrhythmia Management: Methods or Madness, 17(3S):4S
- Comments on Bayesian and Frequentist Analysis and Interpretation of Clinical Trials, 423
- Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415
- Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience, 23
- Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience (erratum), 271
- Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 526
- Decision Rules for Predicting Future Lipid Value in Screening for a Cholesterol Reduction Clinical Trial, 537
- Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM): A Critical Appraisal, 17(3S):28S
- Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201
- A Factorial Survey Study to Assess the Acceptability HIV Vaccine Trial Designs, 209
- Is Evening Primrose Oil of Value in the Treatment of Premenstrual Syndrome?, 60
- Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrhythmias, 17(3S):37S
- Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294
- Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(3S):47S
- Organizational Structure and Communication Strategies of the Bypass Angioplasty Revascularization Investigation: A Multicenter Clinical Trial, 226

Participants' Perceptions of a Phase I
Colon Cancer Chemoprevention
Trial, 494

Physicians' Attitudes Toward Clinical
Trials and Their Relationship to
Patient Accrual in a Nordic
Multicenter Study on Myeloma,
372

Planning Pharmaceutical Clinical Trials
(book review), 73

Post-Myocardial Infarction Trials: Beta
Blockers, Antiarrhythmics,
Thrombolytics, 17(3S):17S

Recent Advances in Clinical Trial Design
and Analysis (book review), 547

Quality of Life and Pharmacoeconomics
in clinical Trials (book review),
548

Registry of Multicenter Clinical Trials:
14th and 15th Report 1992-1993.
On Behalf of the Council on
Thrombosis and Haemostasis of
the International Society and
Federation of Cardiology, and
the Scientific and Standardization
Committee of the International
Society on Thrombosis and
Haemostasis, 130

*Statistics in Medical Research: Developments
in Clinical Trials* (book review),
176

Sudden Cardiac Death: Lessons from
Multicenter Clinical Trials,
17(3S):1S

Thomas C. Chalmers, M.D., 474

Tribute to Dr. Thomas C. Chalmers, 475

Trial of Calcium for Preeclampsia
Prevention (CPEP): Rationale,
Design, and Methods (design
paper), 442

CLOSE-OUT QUESTIONNAIRE

Participants' Perceptions of a Phase I
Colon Cancer Chemoprevention
Trial, 494

COLLABORATIVE RESEARCH

*Exploring Collaborative Research in Primary
Care* (book review), 177

COMMUNICATION

Communication During the Recruitment
Phase of a Multicenter Trial: The
Recruitment Hotline, 415

Organizational Structure and
Communication Strategies of the
Bypass Angioplasty

Revascularization Investigation: A
Multicenter Clinical Trial, 226

COMPUTED TOMOGRAPHY

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

CONDITIONAL POWER

Data Monitoring Committees and
Problems of Lower-Than-
Expected Accrual or Event Rates,
526

CONFIDENCE LEVEL

Uncertainty of the Time of First
Significance in Random Effects
Cumulative Meta-analysis, 357

CORONARY DISEASE

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

COST EFFECTIVENESS ANALYSIS

The Economic Evaluation of the FIRST
Study: Design of a Prospective
Analysis Alongside a
Multinational Phase III Clinical
Trial, 304

Statistical Methods for Cost-Effectiveness
Analyses, 387

CROSS CULTURAL BIOETHICS

Ethical and Cross Cultural Questions
Concerning Pediatric Clinical
Trials, 201

CUMULATIVE META-ANALYSIS

Uncertainty of the Time of First
Significance in Random Effects
Cumulative Meta-analysis, 357

DATA ANALYSIS

Blinding During Data Analysis and
Writing of Manuscripts, 285
Visualizing Data: The New Frontier of
Data Analysis (book review), 435

DATA MANAGEMENT

A World Wide Web-based User Interface
for a Data Management System

- Dietary Intervention to Lower LDL Cholesterol, 33
- Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13
- CHRONIC VIRAL LIVER DISEASE**
- Preliminary Results of Beta-Interferon Treatment in the Elderly, 123
- CLINICAL DECISION MAKING**
- The Economic Evaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304
- CLINICAL EFFECTIVENESS**
- The Economic Evaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304
- CLINICAL INVESTIGATOR**
- The Clinical Investigator as Target, 183
- CLINICAL MEASUREMENT**
- Clinical Measurement in Drug Evaluation* (book review), 354
- CLINICAL TRIAL REGISTRY**
- Registry of Multicenter Clinical Trials: 14th and 15th Report 1992-1993. On Behalf of the Council on Thrombosis and Haemostasis of the International Society and Federation of Cardiology, and the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 130
- CLINICAL TRIALS**
- Analyzing Survival Data from Clinical Trials and Observational Studies* (book review), 353
- Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509
- Clinical Trial Enrollers vs. Nonenrollers: The Cardiac Arrhythmia Suppression Trial (Cast)
- Recruitment and Enrollment Assessment in Clinical Trials (REACT) Project, 46
- Clinical Trials of Arrhythmia Management: Methods or Madness, 17(3S):4S
- Comments on Bayesian and Frequentist Analysis and Interpretation of Clinical Trials, 423
- Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415
- Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience, 23
- Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience (erratum), 271
- Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 526
- Decision Rules for Predicting Future Lipid Value in Screening for a Cholesterol Reduction Clinical Trial, 537
- Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM): A Critical Appraisal, 17(3S):28S
- Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201
- A Factorial Survey Study to Assess the Acceptability HIV Vaccine Trial Designs, 209
- Is Evening Primrose Oil of Value in the Treatment of Premenstrual Syndrome?, 60
- Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrhythmias, 17(3S):37S
- Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294
- Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(3S):47S
- Organizational Structure and Communication Strategies of the Bypass Angioplasty Revascularization Investigation: A Multicenter Clinical Trial, 226

Participants' Perceptions of a Phase I
Colon Cancer Chemoprevention
Trial, 494

Physicians' Attitudes Toward Clinical
Trials and Their Relationship to
Patient Accrual in a Nordic
Multicenter Study on Myeloma,
372

Planning Pharmaceutical Clinical Trials
(book review), 73

Post-Myocardial Infarction Trials: Beta
Blockers, Antiarrhythmics,
Thrombolytics, 17(3S):17S

Recent Advances in Clinical Trial Design
and Analysis (book review), 547

Quality of Life and Pharmacoeconomics
in clinical Trials (book review),
548

Registry of Multicenter Clinical Trials:
14th and 15th Report 1992-1993.
On Behalf of the Council on
Thrombosis and Haemostasis of
the International Society and
Federation of Cardiology, and
the Scientific and Standardization
Committee of the International
Society on Thrombosis and
Haemostasis, 130

*Statistics in Medical Research: Developments
in Clinical Trials* (book review),
176

Sudden Cardiac Death: Lessons from
Multicenter Clinical Trials,
17(3S):1S

Thomas C. Chalmers, M.D., 474

Tribute to Dr. Thomas C. Chalmers, 475

Trial of Calcium for Preeclampsia
Prevention (CPEP): Rationale,
Design, and Methods (design
paper), 442

CLOSE-OUT QUESTIONNAIRE

Participants' Perceptions of a Phase I
Colon Cancer Chemoprevention
Trial, 494

COLLABORATIVE RESEARCH

*Exploring Collaborative Research in Primary
Care* (book review), 177

COMMUNICATION

Communication During the Recruitment
Phase of a Multicenter Trial: The
Recruitment Hotline, 415

Organizational Structure and
Communication Strategies of the
Bypass Angioplasty

Revascularization Investigation: A
Multicenter Clinical Trial, 226

COMPUTED TOMOGRAPHY

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

CONDITIONAL POWER

Data Monitoring Committees and
Problems of Lower-Than-
Expected Accrual or Event Rates,
526

CONFIDENCE LEVEL

Uncertainty of the Time of First
Significance in Random Effects
Cumulative Meta-analysis, 357

CORONARY DISEASE

The Lipoprotein and Coronary
Atherosclerosis Study (LCAS):
Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

COST EFFECTIVENESS ANALYSIS

The Economic Evaluation of the FIRST
Study: Design of a Prospective
Analysis Alongside a
Multinational Phase III Clinical
Trial, 304

Statistical Methods for Cost-Effectiveness
Analyses, 387

CROSS CULTURAL BIOETHICS

Ethical and Cross Cultural Questions
Concerning Pediatric Clinical
Trials, 201

CUMULATIVE META-ANALYSIS

Uncertainty of the Time of First
Significance in Random Effects
Cumulative Meta-analysis, 357

DATA ANALYSIS

Blinding During Data Analysis and
Writing of Manuscripts, 285
Visualizing Data: The New Frontier of
Data Analysis (book review), 435

DATA MANAGEMENT

A World Wide Web-based User Interface
for a Data Management System

for Use in Multi-institutional Clinical Trials—Development and Experimental Operation of an Automated Patient Registration and Random Allocation System, 476

DATA MONITORING

Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 527

DATA QUALITY

Do Low Observed Error Rates Lessen the Need for Study-Specific Data Quality Audits (letter)?, 69

Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

Response to O'Rourke (letter), 71

DESIGN

Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77

DIABETES, NON-INSULIN DEPENDENT

Baseline Characteristics of Participants in the Appropriate Blood Pressure Control in Diabetes Trial, 242

DIAGNOSTIC UNCERTAINTY

Randomized Clinical Trials in the Presence of Diagnostic Uncertainty: Implications for Measures of Efficacy and Sample Size, 191

DICLOFENAC

Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

DIET

Maximizing Recruitment Efforts in a

Drug Lipid-Lowering Trial with Dietary Intervention to Lower LDL Cholesterol, 33

DIGOXIN

Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77

DISEASE PREVENTION

Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

DOUBLE MASKING

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294

DRUG EVALUATION

Clinical Measurement in Drug Evaluation (book review), 354

EARLIEST CUMULATIVE SIGNIFICANCE

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

ECONOMICS

The Economic Evaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304

ELDERLY POPULATIONS

Forecasting the Health of Elderly Populations (book review), 75

Preliminary Results of Beta-Interferon Treatment in the Elderly, 123

END-STAGE RENAL DISEASE

Overview, 17(4S):15

ENROLLMENT

Clinical Trial Enrollers vs. Nonenrollers: The Cardiac Arrhythmia Suppression Trial (Cast) Recruitment and Enrollment Assessment in Clinical Trials (REACT) Project, 46

EPIDEMIOLOGY

Ethics and Epidemiology and Clinical Research (book review), 437

ERROR RATES

Do Low Observed Error Rates Lessen the Need for Study-Specific Data Quality Audits (letter)?, 69
Response to O'Rourke (letter), 71

ETHICS

Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201
Ethics and Epidemiology and Clinical Research (book review), 437
Tribute to Dr. Thomas C. Chalmers, 473

EVENING PRIMROSE OIL

Is Evening Primrose Oil of Value in the Treatment of Premenstrual Syndrome?, 60

FACTORIAL SURVEY

A Factorial Survey Study to Assess the Acceptability HIV Vaccine Trial Designs, 209

FAILURE TIME

A Note on Quantifying Follow-up in Studies of Failure Time, 343

FIALURIDINE (FIAU)

An Open Letter to the FDA Regarding Changes in Reporting Procedures for Drugs and Biologics Proposed in the Wake of the FIAU Tragedy (letter), 273

FLUVASTATIN

The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, Methods, and Baseline Data of a Trial of Fluvastatin in Patients without Severe Hypercholesterolemia, 550

FOLLOW-UP

A Note on Quantifying Follow-up in Studies of Failure Time, 343

FOOD AND DRUG**ADMINISTRATION (FDA)**

An Open Letter to the FDA Regarding Changes in Reporting Procedures for Drugs and

Biologics Proposed in the Wake of the FIAU Tragedy (letter), 273

FORECASTING

Forecasting the Health of Elderly Populations (book review), 75

FREQUENTIST ANALYSIS

Comments on Bayesian and Frequentist Analysis and Interpretation of Clinical Trials, 423

H₂ ANTAGONIST

Differences in Basal Nocturnal, Meal-Stimulated, and Pentagastrin-Stimulated Gastric Secretion Values in a Sample of Healthy Volunteers in Basal Conditions and Under Ranitidine Influence, 258

HEALTH TECHNOLOGY**ASSESSMENT**

Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?, 1

HEART FAILURE

Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77

HEMOSTASIS

Registry of Multicenter Clinical Trials: 14th and 15th Report 1992-1993. On Behalf of the Council on Thrombosis and Haemostasis of the International Society and Federation of Cardiology, and the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 130

HIV

A Factorial Survey Study to Assess the Acceptability HIV Vaccine Trial Designs, 209

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASES/ANTAGONISTS AND INHIBITORS

The Lipoprotein and Coronary Atherosclerosis Study (LCAS):

Design, Methods, and Baseline
Data of a Trial of Fluvastatin in
Patients without Severe
Hypercholesterolemia, 550

HYPERTENSION

- Appointment Attendance, Pill Counts,
and Achievement of Goal Blood
Pressure in the African American
Study of Kidney Disease and
Hypertension Pilot Study,
17(4S):34S
- Baseline Characteristics of Participants in
the Appropriate Blood Pressure
Control in Diabetes Trial, 242
- Community Volunteers as Recruitment
Staff in a Clinical Trial: The
Systolic Hypertension in the
Elderly Program (SHEP)
Experience, 23
- Community Volunteers as Recruitment
Staff in a Clinical Trial: The
Systolic Hypertension in the
Elderly Program (SHEP)
Experience (erratum), 271
- Comparison of Once Daily and Twice
Daily Nisoldipine as
Monotherapy in Essential
Hypertension, 117
- Design and Baseline Characteristics of
Participants in the African
American Study of Kidney
Disease and Hypertension
(AASK) Pilot Study, 17(4S):3S
- Effect of Blood Pressure Control and
Antihypertensive Drug Regimen
on Quality of Life: The African
American Study of Kidney
Disease and Hypertension
(AASK) Pilot Study, 17(4S):40S
- Overview, 17(4S):1S
- Participant Satisfaction in the African
American Study of Kidney
Disease and Hypertension
(AASK) Pilot Study, 17(4S):47S
- Recruitment Experience in the African
American Study of Kidney
Disease and Hypertension
(AASK) Pilot Study, 17(4S):17S
- Trial of Calcium for Preeclampsia
Prevention (CPEP): Rationale,
Design, and Methods (design
paper), 442

HYPERTHERMIA

- Biological Rationale and Clinical
Experience with Hyperthermia,
316

IMPLEMENTATION

- Rationale, Design, Implementation, and
Baseline Characteristics of
Patients in the DIG Trial: A Large,
Simple, Long-Term Trial to
Evaluate the Effect of Digitalis on
Mortality in Heart Failure, 77

INFORMED CONSENT

- Ethical and Cross Cultural Questions
Concerning Pediatric Clinical
Trials, 201

INTENT-TO-TREAT

- Clinical Trials of Arrhythmia
Management: Methods or
Madness, 17(3S):4S
- Electrophysiologic Study Versus
Electrocardiographic Monitoring
(ESVEM): A Critical Appraisal,
17(3S):28S
- Major Clinical Trials Assessing the
Prophylactic Use of Amiodarone
in Patients with Ventricular
Tachyarrhythmias, 17(3S):37S
- Ongoing Risk Stratification Trials: The
Primary Prevention of Sudden
Death, 17(3S):47S
- Post-Myocardial Infarction Trials: Beta
Blockers, Antiarrhythmics,
Thrombolytics, 17(3S):17S

INTERIM ANALYSIS

- Data Monitoring Committees and
Problems of Lower-Than-
Expected Accrual or Event
Rates, 526

INTERNET

- A World Wide Web-based User Interface
for a Data Management System
for Use in Multi-institutional
Clinical Trials—Development
and Experimental Operation of an
Automated Patient Registration
and Random Allocation
System, 476

KAPLAN-MEIER METHOD

- Power Calculation for the Log Rank Test
Using Historical Data, 111

KAPOSI'S SARCOMA

- Sample Size Calculations for Within-
Patient Comparisons with a
Binary or Survival Endpoint, 221

KIDNEY DISEASE

Appointment Attendance, Pill Counts, and Achievement of Goal Blood Pressure in the African American Study of Kidney Disease and Hypertension Pilot Study, 17(4S):34S

Design and Baseline Characteristics of Participants in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):3S

Effect of Blood Pressure Control and Antihypertensive Drug Regimen on Quality of Life: The African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):40S

Overview, 17(4S):1S

Participant Satisfaction in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):47S

Recruitment Experience in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study, 17(4S):17S

LARGE SIMPLE TRIAL

Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digoxin on Mortality in Heart Failure, 77

LIPIDS

Decision Rules for Predicting Future Lipid Value in Screening for a Cholesterol Reduction Clinical Trial, 536

Maximizing Recruitment Efforts in a Drug Lipid-Lowering Trial with Dietary Intervention to Lower LDL Cholesterol, 33

The Lipoprotein and Coronary Atherosclerosis Study (LCAS): Design, Methods, and Baseline Data of a Trial of Fluvastatin in Patients without Severe Hypercholesterolemia, 550

LOG RANK TEST

Power Calculation for the Log Rank Test Using Historical Data, 111

MANAGEMENT

Organizational Structure and

Communication Strategies of the Bypass Angioplasty Revascularization Investigation: A Multicenter Clinical Trial, 226

MASKING

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294

MEAL-STIMULATED SECRETION

Differences in Basal Nocturnal, Meal-Stimulated, and Pentagastrin-Stimulated Gastric Secretion Values in a Sample of Healthy Volunteers in Basal Conditions and Under Ranitidine Influence, 258

MEDICAL RESEARCH

Statistics in Medical Research: Developments in Clinical Trials (book review), 176

META-ANALYSIS

Assessing the Quality of Reports of Randomized Clinical Trials: Is Blinding Necessary?, 1

Is Evening Primrose Oil of Value in the Treatment of Premenstrual Syndrome?, 60

Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13

Thomas C. Chalmers, M.D., 474

Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

MONOTHERAPY

Comparison of Once Daily and Twice Daily Nisoldipine as Monotherapy in Essential Hypertension, 117

MULTICENTER CLINICAL TRIALS

Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415

Physicians' Attitudes Toward Clinical Trials and Their Relationship to Patient Accrual in a Nordic Multicenter Study on Myeloma, 372

Sudden Cardiac Death: Lessons from

Multicenter Clinical Trials,
17(3S):1S

MULTIPLE ENDPOINTS

Approaches to Monitoring the Results of
Long-Term Disease Prevention
Trials: Examples from the
Women's Health Initiative, 509

MULTIPLE MYELOMA

Physicians' Attitudes Toward Clinical
Trials and Their Relationship to
Patient Accrual in a Nordic
Multicenter Study on Myeloma,
372

MULTIVARIATE NORMAL DISTRIBUTION

Decision Rules for Predicting Future
Lipid Value in Screening for a
Cholesterol Reduction Clinical
Trial, 536

MYOCARDIAL INFARCTION

Uncertainty of the Time of First
Significance in Random Effects
Cumulative Meta-analysis, 357

NET BENEFIT

Statistical Methods for Cost-Effectiveness
Analyses, 387

NISOLDIPINE

Comparison of Once Daily and Twice
Daily Nisoldipine as
Monotherapy in Essential
Hypertension, 117

NON-RESPONDER MODELS

Statistical Methods for Cost-Effectiveness
Analyses, 387

NULL HYPOTHESIS TESTING

A Note On Conventional Null
Hypothesis Testing in Active
Control Equivalence Studies
(letter), 347, (letter reply), 349

OBSERVATIONAL STUDIES

*Analyzing Survival Data from Clinical Trials
and Observational Studies* (book
review), 353

ONCOLOGY

Biological Rationale and Clinical
Experience with Hyperthermia,
316

ORGANIZATIONAL STRUCTURE

Organizational Structure and
Communication Strategies of the
Bypass Angioplasty
Revascularization Investigation: A
Multicenter Clinical Trial, 226

OVERVIEW

Is Evening Primrose Oil of Value in the
Treatment of Premenstrual
Syndrome?, 60
Japanese and American Reports of
Randomized Trials: Differences
in the Reporting of Adverse
Effects, 99
Uncertainty of the Time of First
Significance in Random Effects
Cumulative Meta-analysis, 357

PAIN

Assessing the Quality of Reports of
Randomized Clinical Trials: Is
Blinding Necessary?, 1

PARTICIPANT PERCEPTIONS

Participants' Perceptions of a Phase I
Colon Cancer Chemoprevention
Trial, 494

PATIENT ACCRUAL

Physicians' Attitudes Toward Clinical
Trials and Their Relationship to
Patient Accrual in a Nordic
Multicenter Study on Myeloma,
372

PATIENT CONTACT

Remote Clinic/Patient Monitoring for
Multicenter Trials, 407

PEDIATRICS

Ethical and Cross Cultural Questions
Concerning Pediatric Clinical
Trials, 201

PENTAGASTRIN TEST

Differences in Basal Nocturnal, Meal-
Stimulated, and Pentagastrin-
Stimulated Gastric Secretion
Values in a Sample of Healthy
Volunteers in Basal Conditions
and Under Ranitidine Influence,
258

PHARMACEUTICALS

Planning Pharmaceutical Clinical Trials
(book review), 73

PHARMACOECONOMICS

Quality of Life and Pharmacoeconomics
in clinical Trials (book review),
548

PHARMACOEPIDEMOLOGY

Japanese and American Reports of
Randomized Trials: Differences
in the Reporting of Adverse
Effects, 99

PHARMACOKINETICS

*Pharmacokinetics: Regulatory-Industrial-
Academic Perspectives* (book
review), 268

**PHONE CERTIFICATION/
RECERTIFICATION**

Remote Clinic/Patient Monitoring for
Multicenter Trials, 407

PHYSICIANS' ATTITUDES

Physicians' Attitudes Toward Clinical
Trials and Their Relationship to
Patient Accrual in a Nordic
Multicenter Study on Myeloma,
372

PLACEBO

Masking Drug Treatments in the Cardiac
Arrhythmia Pilot Study (CAPS),
294

POWER

Power Calculation for the Log Rank Test
Using Historical Data, 111

PREECLAMPSIA

Trial of Calcium for Preeclampsia
Prevention (CPEP): Rationale,
Design, and Methods (design
paper), 442

PREFERENCE MEASURES

Statistical Methods for Cost-Effectiveness
Analyses, 387

PREGNANCY

Trial of Calcium for Preeclampsia
Prevention (CPEP): Rationale,
Design, and Methods (design
paper), 442

PREMENSTRUAL SYNDROME

Is Evening Primrose Oil of Value in the

Treatment of Premenstrual
Syndrome?, 60

PRIMARY CARE

*Exploring Collaborative Research in Primary
Care* (book review), 177

PROSPECTIVE REGISTER

Development of a Prospective Register of
Smoking Cessation Trials, 235

PROTEINURIA

Trial of Calcium for Preeclampsia
Prevention (CPEP): Rationale,
Design, and Methods (design
paper), 442

QUALITY

Assessing the Quality of Reports of
Randomized Clinical Trials: Is
Blinding Necessary?, 1
Do Low Observed Error Rates Lessen the
Need for Study-Specific Data
Quality Audits (letter)?, 69
Response to O'Rourke (letter), 71

QUALITY OF LIFE

Quality of Life and Pharmacoeconomics
in clinical Trials (book review),
548

QUANTIFICATION

A Note on Quantifying Follow-up in
Studies of Failure Time, 343

RADIATION

Biological Rationale and Clinical
Experience with Hyperthermia,
316

RANDOM EFFECTS MODEL

Uncertainty of the Time of First
Significance in Random Effects
Cumulative Meta-analysis, 357

**RANDOMIZED CONTROLLED
TRIALS**

Assessing the Quality of Reports of
Randomized Clinical Trials: Is
Blinding Necessary?, 1
Clinical Trials of Arrhythmia
Management: Methods or
Madness, 17(35):45
The Economic Evaluation of the FIRST
Study: Design of a Prospective
Analysis Alongside a

- Multinational Phase III Clinical Trial, 304
- Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99
- Maximizing Recruitment Efforts in a Drug Lipid-Lowering Trial with Dietary Intervention to Lower LDL Cholesterol, 33
- Randomized Clinical Trials in the Presence of Diagnostic Uncertainty: Implications for Measures of Efficacy and Sample Size, 191
- Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77
- Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13
- Thomas C. Chalmers, M.D., 474
- Tribute to Dr. Thomas C. Chalmers, 473
- Two Cheers for Bayes (letter), 350, (letter reply), 352
- RANITIDINE**
- Differences in Basal Nocturnal, Meal-Stimulated, and Pentagastrin-Stimulated Gastric Secretion Values in a Sample of Healthy Volunteers in Basal Conditions and Under Ranitidine Influence, 258
- RATIONALE**
- Rationale, Design, Implementation, and Baseline Characteristics of Patients in the DIG Trial: A Large, Simple, Long-Term Trial to Evaluate the Effect of Digitalis on Mortality in Heart Failure, 77
- REACT**
- Clinical Trial Enrollers vs. Nonenrollers: The Cardiac Arrhythmia Suppression Trial (Cast) Recruitment and Enrollment Assessment in Clinical Trials (REACT) Project, 46
- RECRUITMENT**
- Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415
- REGIONAL COORDINATOR**
- Remote Clinic/Patient Monitoring for Multicenter Trials, 407
- RESEARCH SYNTHESIS**
- Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357
- RECOMBINANT GROWTH HORMONE**
- Ethical and Cross Cultural Questions Concerning Pediatric Clinical Trials, 201
- RECRUITMENT**
- Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience, 23
- Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience (erratum), 271
- Maximizing Recruitment Efforts in a Drug Lipid-Lowering Trial with Dietary Intervention to Lower LDL Cholesterol, 33
- REGRESSION**
- Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13
- REGULATORY-INDUSTRIAL-ACADEMIC PERSPECTIVES**
- Pharmacokinetics: Regulatory-Industrial-Academic Perspectives* (book review), 268
- RISK STRATIFICATION TRIALS**
- Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(35):475
- SAFETY MONITORING**
- Approaches to Monitoring the Results of Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

SAMPLE SIZE

- Power Calculation for the Log Rank Test Using Historical Data, 111
- Randomized Clinical Trials in the Presence of Diagnostic Uncertainty: Implications for Measures of Efficacy and Sample Size, 191
- Sample Size Calculations for Within-Patient Comparisons with a Binary or Survival Endpoint, 221

SCREENING

- Decision Rules for Predicting Future Lipid Value in Screening for a Cholesterol Reduction Clinical Trial, 537

SHEP

- Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience, 23
- Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience (erratum), 271

SIMULATION

- Uncertainty of the Time of First Significance in Random Effects Cumulative Meta-analysis, 357

SIMVASTATIN

- Japanese and American Reports of Randomized Trials: Differences in the Reporting of Adverse Effects, 99

SMOKING CESSATION TRIALS

- Development of a Prospective Register of Smoking Cessation Trials, 235

STATISTICS

- Statistics in Medical Research: Developments in Clinical Trials* (book review), 176

STOCHASTIC CURTAILMENT

- Data Monitoring Committees and Problems of Lower-Than-Expected Accrual or Event Rates, 526

STOPPING RULES

- Approaches to Monitoring the Results of

- Long-Term Disease Prevention Trials: Examples from the Women's Health Initiative, 509

SUDDEN CARDIAC DEATH

- Clinical Trials of Arrhythmia Management: Methods or Madness, 17(3S):4S
- Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM): A Critical Appraisal, 17(3S):28S
- Major Clinical Trials Assessing the Prophylactic Use of Amiodarone in Patients with Ventricular Tachyarrhythmias, 17(3S):37S
- Ongoing Risk Stratification Trials: The Primary Prevention of Sudden Death, 17(3S):47S
- Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S
- Sudden Cardiac Death: Lessons from Multicenter Clinical Trials, 17(3S):1S

SURVIVAL DATA

- Analyzing Survival Data from Clinical Trials and Observational Studies* (book review), 353
- Sample Size Calculations for Within-Patient Comparisons with a Binary or Survival Endpoint, 221

TARGET

- The Clinical Investigator as Target, 183

THERMORADIOTHERAPY

- Biological Rationale and Clinical Experience with Hyperthermia, 316

THROMBOLYSIS

- Post-Myocardial Infarction Trials: Beta Blockers, Antiarrhythmics, Thrombolytics, 17(3S):17S

THROMBOSIS

- Registry of Multicenter Clinical Trials: 14th and 15th Report 1992-1993. On Behalf of the Council on Thrombosis and Haemostasis of the International Society and Federation of Cardiology, and the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis, 130

TOTAL MORTALITY

Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13

TREATMENT

Relationship Between Total Mortality and Cholesterol Reduction as Found by Meta-Regression Analysis of Randomized Cholesterol-Lowering Trials, 13

TRIAL DESIGN

The Economic Evaluation of the FIRST Study: Design of a Prospective Analysis Alongside a Multinational Phase III Clinical Trial, 304

Masking Drug Treatments in the Cardiac Arrhythmia Pilot Study (CAPS), 294

Recent Advances in Clinical Trial Design and Analysis (book review), 547

TRIAL MANAGEMENT

Communication During the Recruitment Phase of a Multicenter Trial: The Recruitment Hotline, 415

VACCINES

A Factorial Survey Study to Assess the

Acceptability HIV Vaccine Trial Designs, 209

VOLUNTEER STAFF

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience, 23

Community Volunteers as Recruitment Staff in a Clinical Trial: The Systolic Hypertension in the Elderly Program (SHEP) Experience (erratum), 271

WITHIN-SUBJECT COMPARISONS

Sample Size Calculations for Within-Patient Comparisons with a Binary or Survival Endpoint, 221

WORLD WIDE WEB (WWW)

A World Wide Web-based User Interface for a Data Management System for Use in Multi-institutional Clinical Trials—Development and Experimental Operation of an Automated Patient Registration and Random Allocation System, 476

WRITING OF MANUSCRIPTS

Blinding During Data Analysis and Writing of Manuscripts, 285

